Joaquim Bellmunt: Proud of learning from negative trials

Toni Choueiri shared a post by Joaquim Bellmunt, Director Bladder Cancer Center at Dana-Farber Cancer Institute, on X, addding:

“Congrats to our own Joaquim Bellmunt who leads the bladder cancer efforts.”

Quoting Joaquim Bellmunt’s post:

“Proud of learning from negative trials. ‘Induction avelumab followed by chemoimmunotherapy and maintenance vs chemo alone as f1st line therapy in cis-ineligible mUC (INDUCOMAIN): a randomized phase II study’ is out.”

Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study

Authors: Rodriguez-Vida, B.P. Valderrama, D. Castellano, A. Pinto, B. Mellado, J. Puente, M.A. Climent, M. Domenech, F. Vazquez, J.L. Perez-Gracia, T. Bonfill, R. Morales-Barrera, E. Gonzalez-Billalabeitia, X. Garcia-del-Muro, P. Maroto, N. Navarro-Gorro, N. Juanpere, O. Juan, J. Bellmunt

Source: Toni Choueiri /X and Joaquim Bellmunt/X

Toni Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. He is the Medical Director of International Strategic Initiatives at Dana-Farber and past President of the Medical Staff at DFCI (2016-2018).